tetano
Editor, Senior Moderator
J Infect Dis. (2011) 204 (6): 854-863. doi: 10.1093/infdis/jir440
Immunogenicity of an Inactivated Monovalent 2009 H1N1 Influenza Vaccine in Pregnant Women
Lisa A. Jackson1,
Shital M. Patel2,
Geeta K. Swamy3,
Sharon E. Frey4,
C. Buddy Creech6,
Flor M. Munoz2,
Raul Artal5,
Wendy A. Keitel2,
Diana L. Noah7,
Carey Rodeheffer Petrie8,
Mark Wolff8 and
Kathryn M. Edwards6
+ Author Affiliations
1The Group Health Research Institute, Group Health, Seattle, Washington
2Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, Texas
3Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
4Department of Internal Medicine
5Department of Obstetrics, Gynecology and Women?s Health, Saint Louis University School of Medicine, St. Louis, Missouri
6Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
7Southern Research Institute, Birmingham, Alabama
8The EMMES Corporation, Rockville, Maryland
Correspondence: Lisa Jackson, MD, MPH, Group Health Research Institute, 1730 Minor Ave, Ste 1600, Seattle, WA, 98101 (jackson.l@ghc.org).
Abstract
Background. Although pregnant women are at increased risk of severe illness following influenza infection, there is relatively little information on the immunogenicity of influenza vaccines administered during pregnancy.
Methods. We conducted a clinical trial that enrolled 120 pregnant women in which participants were randomly assigned to receive an inactivated 2009 H1N1 influenza vaccine containing either 25 μg or 49 μg of hemagglutinin (HA) in a 2-dose series with a 21-day period between administration of the first and second doses.
Results. Following the first vaccination, HA inhibition (HAI) titers of ≥1:40 were detected in 93% (95% confidence interval [CI], 82%?98%) of subjects who received the 25-μg dose and 97% (95% CI, 88%?100%) of subjects receiving the 49-μg dose. In cord blood samples, HAI titers of ≥1:40 were found in 87% (95% CI, 73%?96%) of samples from the 25-μg dose group and in 89% (95% CI, 76%?96%) from the 49-μg dose group. Microneutralization titers tended to be higher than HAI titers, but the patterns of response were similar.
Conclusions. In pregnant women, 1 dose of an inactivated 2009 H1N1 influenza vaccine containing 25 μg of HA elicited an antibody response typically associated with protection against influenza infection. Efficient transplacental transfer of antibody was also documented.
Received January 11, 2011.
Accepted June 20, 2011.
http://jid.oxfordjournals.org/content/204/6/854.short
Immunogenicity of an Inactivated Monovalent 2009 H1N1 Influenza Vaccine in Pregnant Women
Lisa A. Jackson1,
Shital M. Patel2,
Geeta K. Swamy3,
Sharon E. Frey4,
C. Buddy Creech6,
Flor M. Munoz2,
Raul Artal5,
Wendy A. Keitel2,
Diana L. Noah7,
Carey Rodeheffer Petrie8,
Mark Wolff8 and
Kathryn M. Edwards6
+ Author Affiliations
1The Group Health Research Institute, Group Health, Seattle, Washington
2Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, Texas
3Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
4Department of Internal Medicine
5Department of Obstetrics, Gynecology and Women?s Health, Saint Louis University School of Medicine, St. Louis, Missouri
6Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
7Southern Research Institute, Birmingham, Alabama
8The EMMES Corporation, Rockville, Maryland
Correspondence: Lisa Jackson, MD, MPH, Group Health Research Institute, 1730 Minor Ave, Ste 1600, Seattle, WA, 98101 (jackson.l@ghc.org).
Abstract
Background. Although pregnant women are at increased risk of severe illness following influenza infection, there is relatively little information on the immunogenicity of influenza vaccines administered during pregnancy.
Methods. We conducted a clinical trial that enrolled 120 pregnant women in which participants were randomly assigned to receive an inactivated 2009 H1N1 influenza vaccine containing either 25 μg or 49 μg of hemagglutinin (HA) in a 2-dose series with a 21-day period between administration of the first and second doses.
Results. Following the first vaccination, HA inhibition (HAI) titers of ≥1:40 were detected in 93% (95% confidence interval [CI], 82%?98%) of subjects who received the 25-μg dose and 97% (95% CI, 88%?100%) of subjects receiving the 49-μg dose. In cord blood samples, HAI titers of ≥1:40 were found in 87% (95% CI, 73%?96%) of samples from the 25-μg dose group and in 89% (95% CI, 76%?96%) from the 49-μg dose group. Microneutralization titers tended to be higher than HAI titers, but the patterns of response were similar.
Conclusions. In pregnant women, 1 dose of an inactivated 2009 H1N1 influenza vaccine containing 25 μg of HA elicited an antibody response typically associated with protection against influenza infection. Efficient transplacental transfer of antibody was also documented.
Received January 11, 2011.
Accepted June 20, 2011.
http://jid.oxfordjournals.org/content/204/6/854.short